全球經心肌雷射血運重建術市場：市場規模、佔有率和趨勢分析（2026-2032 年）

全球經心肌雷射血運重建術市場報告（至2032年）

2025年全球經心肌雷射血運重建術市場規模為750萬美元。預計未來將以-6.2%的複合年成長率萎縮，到2032年達到480萬美元。

本報告涵蓋了經心肌血運重建術(TMR) 裝置的全球市場，包括用於治療不適合其他重組手術的嚴重心絞痛患者的裝置。

該分析包括銷售量、平均售價 (ASP)、市場規模、市場佔有率、成長趨勢、到 2032 年的市場預測以及到 2022 年的歷史數據。

市場需求主要受部分患者良好的臨床療效以及TMR作為無法接受PCI或CABG手術患者的替代療法所驅動。然而，醫生認知度低、存在其他競爭治療方法、缺乏培訓以及醫療設備取得管道有限等因素預計將導致市場萎縮。

市場概覽

全球經心肌雷射血運重建術市場包括用於治療不適合接受標準重組手術的慢性重度心絞痛患者的裝置。

TMR裝置仍然是一種小眾治療方法。它們主要用於一小部分難治性心絞痛患者，這些患者不適合接受冠狀動脈繞道手術手術、經皮冠狀動脈介入治療（PCI）或其他標準治療方法。

隨著微創經導管治療的不斷普及，預計在預測期內市場將會萎縮。這些替代療法正逐漸蠶食原本可能適合接受經導管肌瘤切除術（TMR）的患者族群。

儘管呈下降趨勢，但對於無法透過經皮冠狀動脈介入治療（PCI）或冠狀動脈繞道手術（CABG）治療的缺血區域患者，經心肌缺血再灌注修復術（TMR）仍發揮獨特的臨床作用。這使其市場基礎有限，但預計到2032年，TMR的整體應用範圍將進一步縮小。

市場促進因素

臨床結果

臨床療效仍然是支持繼續使用經心肌消融術（TMR）裝置的關鍵因素之一。來自隨機、多中心臨床試驗的長期追蹤研究表明，患者的生存率有所提高，心絞痛症狀也顯著減輕。

此外，這些研究表明，與僅接受藥物治療的患者相比，同時接受 TMR 系統和藥物治療的患者的運動持續時間更長。

正面的臨床結果將促使醫生和患者在特定情況下考慮經顱磁刺激（TMR）治療。儘管市場規模仍然較小，但鑑於TMR已證實能改善症狀和生活品質，預計它將繼續在治療選擇有限的患者中得到應用。

PCI 和 CABG 的治療方法

許多重度心絞痛患者對藥物治療反應不佳，需要介入治療。大多數情況下，這些患者將接受經皮冠狀動脈介入治療（PCI）或冠狀動脈繞道手術（CABG），並可選擇是否植入支架。

然而，有些患有慢性重度心絞痛的患者並不適合接受經皮冠狀動脈介入治療（PCI）或冠狀動脈繞道手術（CABG）。這可能是由於既往治療失敗、瀰漫性冠狀動脈疾病、遠端狹窄、冠狀動脈非常細小或其他臨床限制所致。

這些患者是TMR的主要目標族群。對於無法透過PCI或CABG治療的缺血區域患者，TMR可以作為一種替代方案，以緩解症狀並改善生活品質。

在難治性心絞痛中發揮獨特作用

TMR在難治性心絞痛的治療中仍扮演著一定的角色。雖然其作用有限，但對於常規治療無效的患者而言，它具有重要的臨床意義。

這些患者可能不適合接受常規手術或介入治療，這限制了他們的治療選擇。當臨床目標是緩解症狀而非透過常規重組直接恢復功能時，可以考慮經導管主動脈瓣置換術（TMR）。

儘管整體市場萎縮，但這種小眾適應症仍維持了對經顱磁振造影（TMR）器械的需求。然而，由於合格的患者群體有限，僅憑此因素預計不足以抵消替代手術出現及其緩慢普及所帶來的壓力。

市場限制

醫生的意識和替代治療方法

鑑於目前治療心絞痛的方案眾多，標靶肌肉修復術（TMR）市場的成長受到限制。許多同類療法為醫生所熟知，並在日常臨床實踐中更常用。

冠狀動脈繞道手術手術（CABG）和經皮冠狀動脈介入治療（PCI）是心血管外科醫師和介入性心臟科醫師經常進行的常見手術。與全分生組織切除術（TMR）相比，這些手術在治療方案中更為成熟，醫師也更為熟悉。

只要TMR雷射治療仍未納入標準治療方案，醫師對其的認知度和興趣就會持續低迷。因此，市場需求預計將繼續停滯不前甚至下降。

培訓和准入限制

由於技術和培訓資源有限，能夠進行和提供經顱磁振造影（TMR）治療的醫生數量有限。該手術需要專門的知識、訓練和專用設備。

TMR裝置需要購買和安裝昂貴的基礎設備。因此，許多醫院對將TMR納入其心絞痛治療方案持謹慎態度。

只有當醫生重新燃起對經顱磁振造影（TMR）手術訓練的興趣和獎勵，以及醫院購買必要的設備時，該技術的普及應用仍將受到限制。這也是市場預計在預測期內萎縮的主要原因之一。

透過微創療法爭奪市場需求

微創經導管療法的快速普及進一步抑制了對完全汞去除術（TMR）的需求。隨著替代治療方法的廣泛應用，符合TMR條件的患者人數預計將會減少。

這一趨勢尤其重要，因為TMR的目標患者群體本來就很小。即使新治療方法造成輕微的蠶食，也可能對市場價值產生重大影響。

隨著醫生和醫院繼續優先考慮熟悉的、創傷較小的、更廣泛可及的手術，預計到 2032 年，全肌肉切除術 (TMR) 本已有限的作用將進一步縮小。

市場範圍和數據範圍

• 量化範圍：市場規模、市場佔有率、市場預測、市場成長率、銷售量、平均售價。
• 定性範圍：市場促進因素和限制因素、競爭分析、近期併購、公司簡介、產品系列和主要競爭對手。
• 目標時期：基準年為 2025 年，預測至 2032 年，歷史資料截至 2022 年。
• 建立市場模型：利用銷售量和平均售價（ASP）分析收入，並輔以競爭佔有率分析和預測假設。
• 目標設備：本報告重點介紹用於治療某些難治性心絞痛患者的經心肌血運重建術設備，這些患者不適合接受 PCI（經皮冠狀動脈介入治療）或 CABG（冠狀動脈繞道手術）。

目標市場及區隔

經心肌雷射血運重建術市場

本部分作為附錄收錄。

本報告涵蓋了全球經經心肌雷射血運重建術市場，這是心臟外科手術和重組技術領域的細分市場。

TMR裝置用於治療某些慢性重度心絞痛患者，這些患者無法透過PCI或CABG有效治療。這些患者可能患有瀰漫性冠狀動脈疾病、遠端狹窄、冠狀動脈非常細小，或有既往治療失敗史。

此市場分析依據市場規模、市場佔有率、市場預測、市場成長率、銷售量及平均售價。

本報告根據難治性心絞痛患者的資格標準、替代治療方法、醫生意識、臨床證據、醫療設備的可及性以及預期的市場萎縮情況，評估了 TMR 的需求。

這種結構使製造商、投資者和策略團隊能夠了解為什麼 TMR 仍然是一個有限的市場，以及替代療法如何改變該領域的長期前景。

競爭分析

全球經心肌雷射血運重建術市場是一個極小眾的市場，規模遠小於大多數心臟外科器械領域。由於經心搏過速血管重建術尚未被廣泛採用為標準治療方法，因此市場競爭較為有限。

這個市場與其說是由廣泛的產品競爭所決定，不如說是由醫療設備的可用性、醫院支持該手術的意願以及醫生在 TMR 技術方面的熟練程度所決定。

由於經顱磁振造影（TMR）需要專用設備和專家培訓，製造商在為其應用創造合適的實施環境方面面臨挑戰。另一方面，醫院可能不願意為這種病例數量有限、目標患者群體狹窄的手術投資設備。

此外，經皮冠狀動脈介入治療（PCI）和冠狀動脈繞道手術（CABG）等成熟的重組方法以及新型經導管治療方法也給該市場帶來了壓力。這些替代療法為醫生所熟知，並持續縮小適合經導管心肌消融術（TMR）的患者群體。

因此，預計在預測期內，該領域的競爭格局將保持有限。進入該領域的公司將不得不依賴小眾的臨床應用案例、現有的實施系統以及對那些不適合採用常規治療方案的患者的持續治療。

科技和醫療治療的發展趨勢

難治性心絞痛的利基應用

TMR 仍專注於一小部分患有難治性心絞痛且無法透過 PCI 或 CABG 治療的患者。

雖然這種有限的臨床作用預計還會持續，但這將無法支持大規模的市場擴張。

臨床結果作為支持因素

長期臨床追蹤研究的良好結果對於證明其繼續使用的合理性至關重要。存活率的提高、心絞痛症狀的減輕以及運動時間的延長，都有助於證明其在特定患者群體中的應用價值。

然而，僅憑此證據不足以使 TMR 成為主流治療方法。

與經皮冠狀動脈介入治療（PCI）和冠狀動脈繞道手術（CABG）的競爭

對於許多重度心絞痛患者而言，經皮冠狀動脈介入治療（PCI）和冠狀動脈繞道手術（CABG）仍然是主要的治療選擇。這些手術對醫生來說更為熟悉，也更為常見。

這限制了人們對TMR（完全混合實境）的認知和興趣。

創傷較小的經導管治療方案

創傷較小的經導管治療正逐漸蠶食全肌肉減容術（TMR）的目標患者族群。隨著這些治療方案的增多，預計接受TMR治療的患者人數將會減少。

預計這一趨勢將在未來繼續限制市場價值。

資本投資障礙

TMR需要昂貴的醫療設備，這對醫院來說是一大障礙。手術量少也使得許多醫療機構難以證明這項投資的合理性。

這限制了人們獲得治療的機會，並減緩了治療的實施。

醫生缺乏培訓

與經皮冠狀動脈介入治療（PCI）和冠狀動脈繞道手術（CABG）相比，接受過經心肌消融術（TMR）訓練的醫師寥寥無幾。除非人們對這項培訓的興趣再次高漲，否則市場可能仍將受到限制。

由於這些訓練方面的限制，預計該程序仍將不在常規治療路徑之內。

地區

本報告涵蓋的全球調查區域包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

• 目前全球經心肌雷射血運重建術市場規模有多大？預計到 2032 年將如何變化？
• 為什麼預計TMR市場在預測期內會萎縮？
• TMR在治療難治性心絞痛患者中扮演什麼角色？
• 哪些類型的患者不適合接受 PCI 或 CABG 手術，而可以考慮 TMR（全肌肉切除術）？
• 臨床結果如何支持在特定病例中繼續使用TMR？
• 醫生對標準療法的認知和偏好限制了其應用，原因是什麼？
• 醫療設備需求如何限制醫院對TMR技術的特定使用？
• 侵入性較小的經導管治療如何使患者免於接受全組織切除術 (TMR)？
• 哪些因素限制了銷售量和市場價值的成長？
• 供應商應該如何評估心臟外科器械這一細分領域的未來？

iData Research 的「全球經心肌雷射血運重建術市場報告」透過器械層面的分析、平均售價 (ASP) 數據、市場佔有率洞察以及到 2032 年的預測來解答這些問題。該報告可用於評估需求、了解細分重組趨勢、分析市場萎縮以及製定全球 TMR 器械市場的產業計畫。

目錄

調查方法

• 第一步：專案啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

• 附錄：經心肌血運重建術市場
• 摘要整理
  • 全球經心肌雷射血運重建術市場概覽
  • 目標程式
  • 目標市場
  • 目標區域
• 介紹
• 市場分析與預測
• 促進因素和抑制因素

簡稱

Global Transmyocardial Revascularization Device Market Report to 2032

The global transmyocardial revascularization device market was valued at $7.5 million in 2025. It is expected to decrease at a compound annual growth rate (CAGR) of -6.2%, reaching $4.8 million by 2032.

This report covers the global market for transmyocardial revascularization (TMR) devices, including devices used to treat selected patients with severe angina who are not candidates for other revascularization procedures.

The analysis includes unit sales, average selling prices (ASPs), market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market demand is supported by positive clinical outcomes in selected patients and the role of TMR as an alternative for patients who cannot undergo PCI or CABG. However, physician awareness, competing procedures, limited training, and restricted access to capital equipment are expected to drive market decline.

Market Overview

The global transmyocardial revascularization device market includes devices used to treat patients with chronic, severe angina who are not suitable candidates for standard revascularization procedures.

TMR devices remain a niche therapy. They are primarily used in a small population of refractory angina patients who are not candidates for coronary artery bypass grafting, percutaneous coronary intervention, or other standard treatment options.

The market is expected to decline over the forecast period as less invasive transcatheter therapies continue to expand. These alternatives have increasingly cannibalized the small patient pool that may have previously been considered for TMR.

Despite this decline, TMR continues to serve a defined clinical role for patients with regions of ischemia that cannot be treated with PCI or CABG. This preserves a limited market base, but the overall role of TMR is expected to diminish further through 2032.

Market Drivers

Clinical Outcomes

Clinical outcomes remain one of the key drivers supporting continued use of TMR devices. Long-term follow-up from randomized, multi-center controlled clinical trials has demonstrated improved survival and significant reductions in angina.

These studies have also shown increased exercise duration in patients treated with TMR systems and medications compared with patients treated with medications alone.

Positive clinical results can help encourage physicians and patients to consider TMR procedures in selected cases. Although the market remains small, evidence of symptom improvement and quality-of-life benefit supports continued use among patients with limited treatment alternatives.

Alternative Treatment to PCI and CABG

Many patients with severe angina do not respond adequately to pharmacological treatment and require a procedural option. In many cases, these patients may be treated with PCI, with or without stenting, or CABG.

However, some patients with chronic, severe angina are not candidates for PCI or CABG. This may be due to prior failed procedures, diffuse coronary artery disease, distal stenosis, extremely small coronary arteries, or other clinical limitations.

These patients represent the primary target population for TMR. For patients with ischemic regions that cannot be treated with PCI or CABG, TMR may offer an alternative method to reduce symptoms and improve quality of life.

Niche Role in Refractory Angina

TMR continues to have a niche role in refractory angina treatment. This role is narrow, but it remains clinically relevant for patients who have exhausted more common treatment options.

Because these patients may not be eligible for traditional surgery or interventional therapy, treatment choices are limited. TMR may be considered when the clinical goal is symptom relief rather than direct restoration through conventional revascularization.

This niche indication helps preserve demand for TMR devices, even as the broader market declines. However, because the eligible patient base is small, this driver is not expected to offset the pressure from alternative procedures and limited adoption.

Market Limiters

Physician Awareness and Alternative Procedures

The TMR market has experienced limited growth due to the crowded field of treatment options available for angina. Many competing therapies are more familiar to physicians and are used more often in daily practice.

CABG and PCI procedures are common and are performed regularly by cardiovascular surgeons and interventional cardiologists. These procedures are more established in treatment pathways and are more familiar to physicians than TMR.

If treatment with TMR lasers remains outside the standard of care, physician awareness and interest will remain low. This is expected to result in continued stagnation and decline in market demand.

Limited Training and Access

Limited access to technology and training restricts the number of physicians who can perform and offer TMR therapy. The procedure requires specialized knowledge, training, and the availability of dedicated equipment.

TMR devices require the sale and installation of an expensive capital equipment base unit. This has discouraged many hospitals from incorporating TMR into their angina treatment programs.

Until there is renewed interest or incentive for physicians to train in TMR procedures, and for hospitals to purchase the required capital equipment, uptake will remain limited. This is one of the main reasons the market is expected to decline over the forecast period.

Cannibalization from Less Invasive Therapies

The rapid adoption of less invasive transcatheter therapies is further constraining TMR demand. As alternative interventions expand, fewer patients are likely to be considered for TMR.

This trend is especially important because the TMR patient pool is already small. Even modest cannibalization from newer therapies can have a noticeable impact on market value.

As physicians and hospitals continue to prioritize familiar, less invasive, and more widely available procedures, the already limited role of TMR is expected to diminish further through 2032.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by competitive share analysis and forecast assumptions.
• Device scope: The report covers transmyocardial revascularization devices used in the treatment of selected refractory angina patients who are not candidates for PCI or CABG.

Markets Covered and Segmentation

Transmyocardial Revascularization Device Market

This segment is captured as an appendix.

The report covers the global transmyocardial revascularization device market as a niche segment within cardiac surgery and revascularization technologies.

TMR devices are used to treat selected patients with chronic, severe angina who cannot be treated effectively with PCI or CABG. These patients may have diffuse coronary artery disease, distal stenosis, extremely small coronary arteries, or previous failed procedures.

The market is analyzed by market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.

The report evaluates TMR demand based on refractory angina patient eligibility, procedural alternatives, physician awareness, clinical evidence, capital equipment access, and forecast market decline.

This structure helps manufacturers, investors, and strategy teams understand why TMR remains a limited market and how alternative therapies are reshaping the long-term outlook for this segment.

Competitive Analysis

The global transmyocardial revascularization device market is highly niche and much smaller than most cardiac surgery device segments. Competitive activity is limited because TMR is not broadly adopted as a standard treatment pathway.

The market is shaped less by broad product competition and more by the availability of capital equipment, hospital willingness to support the procedure, and physician familiarity with TMR technology.

Because TMR requires dedicated equipment and specialized training, manufacturers face a difficult adoption environment. Hospitals may be hesitant to invest in capital equipment for a procedure with limited volume and a narrow patient base.

The market is also pressured by established revascularization approaches such as PCI and CABG, as well as newer transcatheter therapies. These alternatives are more familiar to physicians and continue to reduce the pool of patients considered for TMR.

As a result, the competitive landscape is expected to remain limited over the forecast period. Companies participating in the segment must rely on niche clinical use cases, existing installed systems, and continued treatment of patients who are not suitable for more common procedures.

Technology and Practice Trends

Niche Use in Refractory Angina

TMR remains focused on a small group of patients with refractory angina who cannot be treated with PCI or CABG.

This narrow clinical role is expected to continue, but it will not support broad market expansion.

Clinical Outcomes as a Support Factor

Positive outcomes from long-term clinical follow-up remain important for supporting continued use. Improved survival, reduced angina, and increased exercise duration can help justify use in selected patients.

However, this evidence has not been enough to make TMR a mainstream treatment.

Competition from PCI and CABG

PCI and CABG remain the dominant procedural options for many patients with severe angina. These procedures are more familiar to physicians and are performed far more often.

This limits awareness and interest in TMR.

Less Invasive Transcatheter Alternatives

Less invasive transcatheter therapies are increasingly cannibalizing the TMR patient pool. As these options expand, fewer patients are likely to be referred for TMR.

This trend is expected to continue limiting market value.

Capital Equipment Barriers

TMR requires expensive capital equipment, which creates a barrier for hospitals. Low procedural volume makes it difficult for many facilities to justify investment.

This limits access and slows adoption.

Limited Physician Training

Few physicians are trained to perform TMR procedures compared with PCI or CABG. Without renewed training interest, the market will remain constrained.

Training limitations are expected to keep the procedure outside routine treatment pathways.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global transmyocardial revascularization device market today, and how is it expected to change through 2032?
• Why is the TMR market expected to decline over the forecast period?
• What role does TMR play in treating refractory angina patients?
• Which patients are not candidates for PCI or CABG and may be considered for TMR?
• How do clinical outcomes support continued use in selected cases?
• Why do physician awareness and standard-of-care preferences limit adoption?
• How do capital equipment requirements restrict hospital access to TMR technology?
• How are less invasive transcatheter therapies cannibalizing the TMR patient pool?
• What factors are constraining unit sales and market value growth?
• How should suppliers evaluate the future of this niche cardiac surgery device segment?

The Global Transmyocardial Revascularization Device Market Report from iData Research answers these questions with device-level analysis, ASP data, market share insights, and forecasts through 2032. Use it to evaluate demand, understand niche revascularization trends, assess market decline, and support commercial planning in the global TMR device market.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

• Appendix: Transmyocardial Revascularization Market
• 27.1 Executive Summary
  • 27.1.1 Global Transmyocardial Revascularization Device Market Overview
  • 27.1.2 Procedures Included
  • 27.1.3 Markets Included
  • 27.1.4 Regions Included
• 27.2 Introduction
• 27.3 Market Analysis And Forecast
• 27.4 Drivers And Limiters
  • 27.4.1 Market Drivers
  • 27.4.2 Market Limiters

Abbreviations

LIST OF CHARTS

• Chart 27-1: Transmyocardial Revascularization Device Market, Global, 2025 & 2032
• Chart 27-2: Transmyocardial Revascularization Device Procedures, Global, 2025
• Chart 27-3: Transmyocardial Revascularization Market, Global, 2022 - 2032

LIST OF FIGURES

• Figure 27-1: Transmyocardial Revascularization Device Procedures Covered
• Figure 27-2: Transymyocardial Revascularization Device Markets Covered
• Figure 27-3: Transmyocardial Revascularization Device Regions Covered, Global (1 of 2)
• Figure 27-4: Transmyocardial Revascularization Device Regions Covered, Global (2 of 2)
• Figure 27-5: Market Value by Region, Transmyocardial Revascularization Market, Global, 2022 - 2032 (US$M)